Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of using such antibodies and antigen-binding fragments thereof for the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.

Abstract: The present disclosure provides SARS-CoV-2 spike proteins and trimers containing such spike proteins. The present disclosure also provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2. The proteins, trimers, and antibodies can be used, for example, to detect anti-SARS-CoV-2 antibodies in sample obtained from a subject.

Abstract: The present disclosure is directed to methods of treating subjects colonized with S aureus with an anti-alpha toxin antibody or antigen-binding fragment thereof. The methods can decrease the incidence of infection attendant to the presence of S. aureus in the subject.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of using such antibodies and antigen-binding fragments thereof for the prevention and treatment of Coronavirus Disease 2019 (COVID-19) in a subject.

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.

Abstract: Provided herein are methods of preventing and treating a bacterial infection, e.g., a Staphylococcus aureus infection, in a patient, comprising administering to the patient an effective amount of an anti-alpha toxin antibody or an antigen-binding fragment thereof, such as MEDI4893.

Abstract: The present invention relates to an immunoassay for simultaneously measuring the presence of antibodies to a plurlity of HPV types that utilizes particle-based flow cytometric analysis. The presence and/or titre of neutralizing antibodies in a test sample are determined in a competitive format, where known, type-specific, fluorescently labeled neutralizing monoclonal antibodies compete with antibodies within a test sample for binding to conformationally sensitive, neutralizing epitopes on specific HPV-VLPs. The invention also provides a microsphere complex comprising a microsphere coupled to an HPV VLP.

Abstract: The present invention relates generally to novel processes for covalently conjugating polysaccharides to microspheres or other biomolecules, and more specifically to the use of 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methyl-morpholinium chloride (DMTMM) in said processes